Skip to content

Iovance Biotherapeutics

US · IOVA #1864 by market cap Listed 1970
6.90 -0.41 -5.61%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 33 in the most recent period (2026/Q3).
  • Total institutional ownership fell 0.9 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
62.91% -0.94pp
Institutions
369 +33
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund36.67%
Hedge Fund11.91%
Individual/Insider6.42%
VC/PE Fund6.26%
Public Company4.18%
Private Company2.70%
Insurance Company0.81%
Government Pension Fund0.32%
Other30.69%

Top holders as of 2026-09-30

BlackRock 8.19% · 37.90M sh
MHR Fund Management LLC 6.26% · 28.97M sh
Wayne Rothbaum 6.07% · 28.07M sh
State Street Global Advisors 4.69% · 21.70M sh
Two Sigma Investments, LP 4.11% · 19.01M sh
Vanguard Capital Management, LLC 3.98% · 18.40M sh
Vanguard Portfolio Management, LLC 2.65% · 12.28M sh
Geode Capital Management, LLC 2.26% · 10.45M sh
Millennium Management LLC 1.84% · 8.53M sh
Dimensional Fund Advisors 1.35% · 6.24M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 30 buys · 20 sells

NameRoleStake
Wayne Rothbaum Independent Director 6.07%
Frederick Vogt Interim CEO, President, General Counsel, Corporate Secretary & Director 0.13%
Raj Puri Chief Regulatory Officer 0.06%
Daniel Kirby Chief Commercial Officer 0.03%
Igor Bilinsky Chief Operating Officer 0.03%
Michael Weiser Independent Director 0.03%
Friedrich Graf Finckenstein Former Chief Medical Officer 0.03%
Matthew Rosinack Former Senior VP of Finance, Interim Principal Financial Officer & Principal Accounting Officer 0.02%
Iain Dukes Independent Chairperson 0.01%
Corleen Roche Chief Financial Officer 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-10 Frederick Vogt Interim CEO, President, General Counsel, Corporate Secretary & Director Derivative Exercise and Sale -191,303 $7.55–8.09
2026-11-10 Frederick Vogt Interim CEO, President, General Counsel, Corporate Secretary & Director Derivative Exercise and Retained +8,697 $7.55
2026-11-09 Daniel Kirby Chief Commercial Officer Derivative Exercise and Sale -3,935 $8.08
2026-11-09 Daniel Kirby Chief Commercial Officer Derivative Exercise and Retained +6,065 --
2026-11-05 Corleen Roche Chief Financial Officer Derivative Exercise and Sale -5,311 $8.04
2026-11-05 Corleen Roche Chief Financial Officer Derivative Exercise and Retained +7,189 --
2026-09-29 Noah Berkowitz Chief Medical Officer Other Derivative Acquisition +135,000 $14.82
2026-09-29 Noah Berkowitz Chief Medical Officer Other Derivative Acquisition +180,000 --
2026-09-07 Igor Bilinsky Chief Operating Officer Derivative Exercise and Sale -3,976 $8.70
2026-09-07 Igor Bilinsky Chief Operating Officer Derivative Exercise and Retained +3,837 --
2026-09-07 Frederick Vogt Interim CEO, President, General Counsel, Corporate Secretary & Director Derivative Exercise and Sale -6,638 $8.70
2026-09-07 Frederick Vogt Interim CEO, President, General Counsel, Corporate Secretary & Director Derivative Exercise and Retained +8,988 --
2026-09-07 Raj Puri Chief Regulatory Officer Derivative Exercise and Sale -4,478 $8.70
2026-09-07 Raj Puri Chief Regulatory Officer Derivative Exercise and Retained +5,288 --
2026-08-31 Igor Bilinsky Chief Operating Officer Derivative Exercise and Sale -4,472 $8.28
2026-08-31 Igor Bilinsky Chief Operating Officer Derivative Exercise and Retained +4,317 --
2026-08-31 Frederick Vogt Interim CEO, President, General Counsel, Corporate Secretary & Director Derivative Exercise and Sale -17,702 $8.28
2026-08-31 Frederick Vogt Interim CEO, President, General Counsel, Corporate Secretary & Director Derivative Exercise and Retained +23,967 --
2026-08-31 Raj Puri Chief Regulatory Officer Derivative Exercise and Sale -2,508 $8.28
2026-08-31 Raj Puri Chief Regulatory Officer Derivative Exercise and Retained +2,962 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:59:47 · For reference only, not investment advice and not tailored to your situation.

Iovance Biotherapeutics discussion 0 comments

Add a comment